📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
₹7,932 Cr Revenue in Q1 FY27; Order Book Surges to ₹61,500 Cr
Waaree Energies reported a robust Q1 FY27 with revenue growing 79.2% YoY to ₹7,932 Cr, driven by strong module sales and a 130% surge in retail revenue. The order book has reached a massive ₹61,500 Cr, representing approximately 232% of TTM revenue, providing high visibility for the next 2-3 years. While top-line growth was strong, Operating EBITDA margins compressed to 18.2% from 22.5% YoY, leading to a more moderate PAT growth of 15.4% at ₹892 Cr. The company reaffirmed its aggressive FY27 EBITDA guidance of ₹7,000–₹7,700 Cr.
Confidence: HIGH
What changedThe company has significantly scaled its order book to ₹61,500 Cr and shifted its revenue mix towards higher-margin retail (30%) and US domestic sales.
Why it mattersThe massive order book (2.3x TTM revenue) provides long-term revenue security, while backward integration into solar cells is intended to protect margins against supply chain fluctuations.
Q1 FY27 Revenue: ₹7,931.79 CrOrder Book: ₹61,500 CrOrder Book vs TTM Revenue: ~232%FY27 EBITDA Guidance: ₹7,000 - ₹7,700 CrRetail Revenue Growth: 130%Module Capacity: ~26 GW
📅 Short termThe strong revenue growth and massive order book addition are likely to be viewed positively by the market, though margin compression may be a point of scrutiny.
📈 Long termThe transition to a fully integrated energy player with 26 GW module and 5.4 GW cell capacity positions the company to capture a larger share of the global energy transition market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- EBITDA margin contraction (18.2% vs 22.5% YoY)
- High dependency on US trade policies for export revenue
- Execution risk of large-scale integrated manufacturing
Key Highlights
Revenue from operations increased 79.2% YoY to ₹7,931.79 Cr for Q1 FY27.
Total order book stands at ~₹61,500 Cr as of July 28, 2026, with ₹16,000 Cr in new orders added during the period.
Retail revenue grew 130% YoY to ₹1,322 Cr, now accounting for 30.2% of the total revenue mix.
Operating EBITDA stood at ₹1,440 Cr with a margin of 18.2%, compared to 22.5% in the same quarter last year.
Acquired a 55% stake in Associated Power Structures for ~₹1,225 Cr to enhance EPC and transmission capabilities.
👀 What to Watch
Watch for the stabilization of EBITDA margins as the 5.4 GW cell capacity ramps up and the company executes its high-value US domestic manufacturing strategy. Monitor the impact of global solar cell price volatility on the integrated margin profile.
118.8 MW Solar Capacity Commissioned at Neemuch Solar Park
Waaree Energies has successfully commissioned 118.8 MW of solar power capacity at the Neemuch Solar Park in Madhya Pradesh as of July 28, 2026. This represents approximately 70% of the total 170 MW planned capacity for Unit 3 of the facility. While the company's core strength lies in its 12 GW solar module manufacturing capacity, this commissioning demonstrates continued execution in its solar power facility segment. The project will contribute to the company's operational revenue stream as it scales its integrated energy presence.
Confidence: HIGH
What changedWaaree Energies has transitioned 118.8 MW of solar capacity from the construction phase to the operational phase at its Madhya Pradesh site.
Why it mattersThis commissioning validates the company's execution capabilities in the solar power facility segment, providing a diversified revenue stream alongside its primary solar module manufacturing business.
Commissioned Capacity: 118.8 MWTotal Unit 3 Capacity: 170 MWCommissioning Date: 28th July 2026TTM Revenue: ₹26,537 Cr
📅 Short termThe announcement reflects steady operational progress and is likely to be viewed positively by the market as a sign of project execution reliability.
📈 Long termWhile small relative to the 12 GW manufacturing base, such projects support the company's long-term strategy to become an integrated player in the renewable energy value chain.
Key Highlights
Commissioned 118.8 MW of solar power capacity on July 28, 2026
Total planned capacity for Unit 3 of the Neemuch Solar Park facility is 170 MW
Project is located in Madhya Pradesh, contributing to the company's domestic utility-scale footprint
Company currently operates a massive 12 GW module manufacturing capacity as per latest filings
👀 What to Watch
Investors should monitor the commissioning timeline for the remaining 51.2 MW of Unit 3 and track the revenue contribution from the EPC and power generation segments in upcoming quarterly results.
79% Revenue Growth in Q1 FY27; Order Book Reaches ₹61,500 Cr
Waaree Energies reported a robust Q1 FY27 with revenue surging 79.22% YoY to ₹7,931.79 Cr, driven by a 41.51% increase in module production to 3.24 GW. The company added approximately ₹16,000 Cr in new orders during the quarter, taking its total order book to a record ₹61,500 Cr, which is roughly 2.3x its TTM revenue. While Operating EBITDA grew 44.38% YoY to ₹1,439.92 Cr, EBITDA margins compressed to 18.15% from 22.53% in the previous year's quarter. The company reaffirmed its FY27 EBITDA guidance of ₹7,000–7,700 Cr and is progressing with its 10 GW cell facility and new BESS manufacturing.
Confidence: HIGH
What changedThe company has significantly scaled its order book and officially commenced its diversification into Battery Energy Storage Systems (BESS) and power infrastructure through the acquisition of Associated Power Structures.
Why it mattersThe massive order book provides revenue visibility for over two years, while the shift toward 'Waaree 2.0' (integrated energy transition) aims to reduce dependency on pure module manufacturing and capture more value across the renewable chain.
Order Book vs TTM Revenue: 231.7%New Orders Added: ₹16,000 CrQ1 FY27 Revenue: ₹7,931.79 CrEBITDA Margin (YoY Change): -438 bpsFY27 EBITDA Guidance: ₹7,000–7,700 Cr
📅 Short termThe strong top-line growth and massive order book addition are likely to be viewed positively by the market, though the margin contraction may temper some enthusiasm.
📈 Long termThe transition to an integrated player with 10 GW of cell capacity and BESS capabilities positions the company to benefit from structural tailwinds in global energy transition, provided execution remains disciplined.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant YoY margin compression (from 22.5% to 18.1%)
- Execution risk on the large-scale 10 GW cell facility
- Potential impact of international trade policies on export revenues
Key Highlights
Revenue from operations grew 79.22% YoY to ₹7,931.79 Cr
Total order book reached ₹61,500 Cr, including ₹16,000 Cr of new orders added in Q1
Module production increased 41.51% YoY to 3.24 GW for the quarter
Operating EBITDA stood at ₹1,439.92 Cr with a margin of 18.15%
Commenced 5.15 GWh automated BESS container manufacturing in Rola, Gujarat
👀 What to Watch
Investors should monitor the execution timeline of the 10 GW cell facility in Gujarat, as backward integration is key to recovering the 438 bps YoY margin compression. Watch for the contribution of the new BESS and power infrastructure segments in upcoming quarters to see if they diversify the margin profile.
Rs 282 Cr Duty Refund Recognized in Q1; US Customs Investigation and Enel Arbitration Continue
Waaree Energies reported its Q1 FY27 results, notably recognizing Rs 282.30 Cr as other operating revenue from US duty refunds. The company continues to navigate significant legal and regulatory hurdles, including an ongoing US Customs (CBP) investigation into component origins and a Rs 792 Cr arbitration dispute with Enel Green Power. Operationally, the company infused Rs 150 Cr into its energy storage subsidiary in July 2026. As of June 30, 2026, Rs 1,151.32 Cr of IPO proceeds remain unutilized, primarily earmarked for solar manufacturing expansion.
Confidence: HIGH
What changedThe company has moved from a provision-heavy phase to recognizing duty refunds, while simultaneously entering formal arbitration over a major acquisition.
Why it mattersWith 47% of revenue coming from exports (primarily the US), regulatory clarity on component sourcing is vital for maintaining margins and market access.
US Duty Refund Recognized: Rs 282.30 CrEnel Acquisition Dispute Value: Rs 792.00 CrSubsidiary Revenue (53 units): Rs 1,185.25 CrUnutilized IPO Funds: Rs 1,151.32 CrEnergy Storage Infusion: Rs 150.00 Cr
📅 Short termThe recognition of the Rs 282 Cr refund is a positive liquidity event, but the ongoing US investigation and Enel arbitration may create price volatility in the coming weeks.
📈 Long termThe company's structural growth depends on successfully commissioning its 5.4 GW solar cell facility and resolving US trade compliance issues to protect its high-margin export business.
⚠ Risk flags
- US Customs (CBP) investigation into component origins
- Arbitration with Enel Green Power for Rs 792 Cr
- Ongoing Income Tax investigation (since Nov 2025)
Key Highlights
Recognized Rs 282.30 Cr as other operating revenue from US duty refunds following a US Supreme Court verdict.
Ongoing arbitration with Enel Green Power regarding the Rs 792 Cr acquisition of its Indian unit.
Infused Rs 150 Cr into Waaree Energy Storage Solutions on July 8, 2026, for capacity expansion.
US Customs (CBP) investigation continues; company previously recognized a provision of Rs 294.78 Cr in FY26.
Unutilized IPO proceeds stand at Rs 1,151.32 Cr out of the total Rs 3,600 Cr raised.
👀 What to Watch
Investors should monitor the final determination from the US CBP regarding anti-dumping/countervailing duties (AD/CVD) and the outcome of the Enel arbitration, as these will impact cash reserves and expansion plans.
₹32.33 Cr Default: MT Educare Reports Ongoing Repayment Failures Under CIRP
MT Educare Limited has disclosed a total default of ₹32.33 crore in principal and interest payments to Prudence ARC and Axis Bank as of June 30, 2026. The company has been under the Corporate Insolvency Resolution Process (CIRP) since December 16, 2022, and these defaults have been ongoing since March 2021. Additionally, corporate guarantees totaling approximately ₹23.99 crore have been invoked by lenders for subsidiary obligations. A separate ₹49.72 crore claim by SVC Bank is currently under appeal at the NCLAT after being rejected by the NCLT.
Confidence: HIGH
What changedThis filing provides a mandatory update on the company's continued failure to meet debt obligations while undergoing insolvency proceedings.
Why it mattersThe total default and invoked guarantees (exceeding ₹56 crore) are nearly 4x the company's current market capitalization of ₹14 crore, highlighting the extreme financial distress and the high probability of a total loss for equity shareholders.
Total Default Amount: ₹32.33 CrDefault vs Market Cap: 231%Invoked Corporate Guarantees: ₹23.99 CrRejected SVC Bank Claim (under appeal): ₹49.72 CrTTM Revenue: ₹36 Cr
📅 Short termThe stock is likely to remain under severe pressure or trade with high volatility as the insolvency process continues without a clear resolution.
📈 Long termThe long-term survival of the company depends entirely on the NCLT resolution process; structural recovery is unlikely without a massive debt haircut and potential change in ownership.
⚠ Risk flags
- Corporate Insolvency Resolution Process (CIRP)
- Invoked corporate guarantees
- Ongoing litigation at NCLAT
- Negative ROCE (-4.5%)
Key Highlights
Total outstanding borrowings from banks and financial institutions stand at ₹32.33 crore as of the disclosure date.
Default to Prudence ARC includes ₹16.44 crore principal and ₹3.75 crore interest at a 13.75% rate.
Axis Bank default comprises ₹7.65 crore principal and ₹4.51 crore interest across term loans and overdrafts.
Invoked corporate guarantees include ₹16.69 crore for Lakshya Forum and ₹7.3 crore for Sri Gayatri Education Society.
The company remains under CIRP with a Resolution Professional (Arihant Nenawati) managing affairs since January 2024.
👀 What to Watch
Monitor the NCLAT's upcoming decision regarding the ₹49.72 crore SVC Bank claim and any updates on the resolution plan from the Committee of Creditors. Investors should be aware that equity value is often significantly impaired or wiped out during insolvency proceedings.
Rs 7.48 Cr Net Loss in Q1; Revenue Declines 24% YoY to Rs 5.88 Cr
RSSOFTWARE reported a consolidated net loss of Rs 7.48 Cr for Q1 FY27, widening from a loss of Rs 3.61 Cr in the same quarter last year. Revenue from operations fell 24.3% YoY to Rs 5.88 Cr, primarily due to a sharp decline in the USA segment revenue which dropped from Rs 4.35 Cr to Rs 0.55 Cr. Operational stress remains high as employee benefit expenses of Rs 7.42 Cr continue to exceed total revenue from operations. The company also announced the appointment of M/s. Deoki Bijay & Co. as the new Internal Auditor effective August 1, 2026.
Confidence: HIGH
What changedThe company reported a significant YoY decline in revenue and a widening net loss, alongside a change in its internal auditing firm.
Why it mattersThe persistent gap between revenue and employee costs (OPM at -92% TTM) indicates severe operational inefficiency and a high cash burn rate for a company with only Rs 82 Cr market cap.
Revenue (Q1 FY27): Rs 5.88 CrNet Loss (Q1 FY27): Rs 7.48 CrEmployee Cost to Revenue Ratio: 126.1%USA Segment Revenue: Rs 0.55 CrRest of World (ROW) Revenue: Rs 5.33 Cr
📅 Short termThe stock is likely to face downward pressure due to the widening losses and the sharp contraction in its primary US market segment.
📈 Long termThe long-term outlook remains highly speculative and depends entirely on the successful global scaling of its UPI-based payment infrastructure and transaction fee revenue.
⚠ Risk flags
- Operating expenses exceed total revenue
- Significant decline in core USA market revenue
- High employee cost concentration
- Negative ROCE and persistent losses
Key Highlights
Revenue from operations decreased 24.3% YoY to Rs 5.88 Cr from Rs 7.77 Cr
Consolidated net loss widened to Rs 7.48 Cr compared to a loss of Rs 3.61 Cr in Q1 FY26
Employee benefit expenses of Rs 7.42 Cr represent 126% of the quarterly revenue from operations
USA segment revenue plummeted 87% YoY to Rs 55.46 Lakhs from Rs 434.60 Lakhs
Finance costs surged significantly to Rs 35.01 Lakhs from just Rs 0.87 Lakhs in the year-ago period
👀 What to Watch
Investors should monitor the company's transition from fixed-price software development to transaction-based revenue models, as current operating costs are unsustainable relative to income.
ARE&M schedules July 30 plant visit for analysts at new ₹9,500 Cr Li-ion project facility
Amara Raja Energy & Mobility (ARE&M) has scheduled a plant visit for institutional investors and analysts on July 30, 2026. The visit focuses on the recently inaugurated Customer Qualification Plant (CQP) of its subsidiary, Amara Raja Advanced Cell Technologies (ARACT). This facility is a critical milestone in the company's massive ₹9,500 Cr planned investment into Lithium-ion cell manufacturing. The visit allows the investment community to assess progress toward the company's target of achieving 7-8% of revenue from the New Energy segment by FY27.
Confidence: HIGH
What changedThe company is opening its newly inaugurated Lithium-ion Customer Qualification Plant to external analyst scrutiny, signaling a transition from construction to the product qualification phase.
Why it mattersThis is a tangible step in ARE&M's pivot from traditional lead-acid batteries to Lithium-ion technology, which is essential for long-term growth in the EV and energy storage markets.
Planned Li-ion Investment: ₹9,500 CrInvestment vs Market Cap: ~59.4%Target New Energy Revenue (FY27): 7-8%TTM Revenue: ₹13,814 CrVisit Date: July 30, 2026
📅 Short termThe visit may improve market sentiment as it provides physical evidence of execution on the company's ambitious New Energy roadmap.
📈 Long termThe success of the ARACT giga factory is structural to the company's valuation, as it addresses the existential threat posed by the global shift away from lead-acid batteries.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the large-scale ₹9,500 Cr capex
- Geographic concentration in Andhra Pradesh
- Technology obsolescence in the fast-evolving battery sector
Key Highlights
Plant visit scheduled for July 30, 2026, at the Customer Qualification Plant (CQP) in Andhra Pradesh.
The facility is part of a ₹9,500 Cr long-term investment plan for a Lithium-ion giga factory.
The New Energy segment is targeted to contribute 7-8% of total revenue by FY27, up from ~5% expected in FY25.
ARACT, the entity hosting the visit, is a 100% wholly-owned subsidiary of ARE&M.
The total planned investment of ₹9,500 Cr represents approximately 59% of the company's current market capitalization of ₹15,996 Cr.
👀 What to Watch
Investors should monitor post-visit analyst reports for updates on the CQP's operational readiness and the specific timeline for commercial cell production from the upcoming giga factory.
Waaree RTL Enters New Zealand Market via ECI Agreement for Solar + BESS Project
Waaree Renewable Technologies Limited (WRTL) has signed an Early Contractor Involvement (ECI) Agreement for a utility-scale solar PV and Battery Energy Storage System (BESS) project in New Zealand. This marks the company's strategic entry into the Australia and New Zealand (ANZ) market, partnering with two local companies in a consortium. The ECI phase is scheduled for approximately 4 months, after which a formal EPC contract may be signed. While the contract value is currently not disclosed, the project carries a potential 24-month execution timeline upon finalization.
Confidence: HIGH
What changedThe company has secured its first formal engagement in the New Zealand market, moving beyond its primary domestic focus into international utility-scale solar and BESS projects.
Why it mattersThis validates the company's strategy to expand into international markets and integrate BESS into its EPC offerings, potentially diversifying its revenue streams beyond the Indian market.
ECI Validity Period: ~4 monthsPotential Execution Timeline: 24 monthsUnexecuted Order Book: 3.48 GWpFY25 Revenue: ₹ 1,597.75 crOrder Value: not disclosed
📅 Short termThe announcement is sentiment-positive as it demonstrates international reach, though immediate financial impact is limited until the ECI converts to a signed EPC contract.
📈 Long termSuccessful execution in New Zealand could establish a track record for WRTL in developed markets and BESS integration, supporting its long-term growth target of 81%.
⚠ Risk flags
- Conversion risk (ECI does not guarantee a final EPC contract)
- Execution risk in a new international geography
- Potential for fixed-price contract risks in a volatile commodity environment
Key Highlights
Strategic entry into the Australia and New Zealand (ANZ) renewable energy market
ECI Agreement valid for a period of ~4 months for preliminary project development
Potential project execution timeline of 24 months upon signing of the final EPC contract
Project involves integration of Battery Energy Storage System (BESS), a key strategic growth area
Consortium includes two experienced local companies to facilitate international execution
👀 What to Watch
Monitor the conversion of this ECI agreement into a formal EPC contract over the next 4-5 months and look for disclosures regarding the total order value and margin profile.
Bajaj Healthcare targets ₹1,000 Cr revenue in 3 years; Q1 FY27 PAT up 14% to ₹13.9 Cr
Bajaj Healthcare reported a steady Q1 FY27 with revenue growing 11.3% YoY to ₹165.6 Cr and PAT rising 14.1% to ₹13.9 Cr. The company is undergoing a structural shift toward high-value segments, including Peptides and Oncology, with a new 250 kg/annum peptide facility slated for Q4 FY27. Management has provided a clear growth guidance of 10-15% for FY27 and a long-term revenue target of ₹900-1,000 Cr within 2-3 years. Notably, the balance sheet has deleveraged significantly, with the Debt-to-Equity ratio falling to 0.45 from 1.19 in FY24.
Confidence: HIGH
What changedThe company has transitioned from a routine API manufacturer to a high-value specialty player with a focus on Peptides and Oncology, backed by a much stronger balance sheet.
Why it mattersThe shift toward high-margin science-led APIs and specialized formulations (like Cenobamate) is expected to structurally improve EBITDA margins and drive a significant scale-up in revenue over the next 3 years.
Q1 FY27 Revenue: ₹165.6 CrRevenue Growth (YoY): 11.3%Long-term Revenue Target: ₹1,000 CrDebt-to-Equity Ratio: 0.45Peptide Plant Capacity: 250 kg/annumR&D Spend (% of sales): 2.2%
📅 Short termThe stock may react positively to the margin expansion (Gross Margin up 210 bps) and the clear 10-15% growth guidance for the current fiscal year.
📈 Long termThe company's pivot to complex molecules and oncology, combined with a target to double revenue in 3 years, suggests a potential re-rating if execution timelines for new plants are met.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in commissioning high-tech peptide and oncology facilities
- Regulatory delays in NCLT approval for the GenRx acquisition
- Geopolitical risks impacting export pricing and oil-linked API costs
Key Highlights
Q1 FY27 revenue increased 11.3% YoY to ₹165.6 Cr, driven by 27% growth in domestic API.
Management set a long-term revenue target of ₹900-1,000 Cr, representing ~138% growth over TTM revenue of ₹420 Cr.
Debt-to-Equity ratio improved to 0.45 from 1.19 in FY24, reflecting significant deleveraging.
New 250 kg/annum peptide manufacturing facility targeted for commissioning by Q4 FY27.
R&D spending as a percentage of sales scaled from 0.4% in 2024 to 2.2% in 2026.
👀 What to Watch
Watch for the timely commissioning of the peptide facility in Q4 FY27 and the NCLT approval for the GenRx facility acquisition, as these are critical for the company's ₹1,000 Cr revenue roadmap.
₹448.1 Cr Q1-FY27 Revenue: Share India Reports 44.77% EBITDA Margin and Diversified Growth
Share India Securities reported a strong Q1-FY27 with revenue reaching ₹448.1 Cr, which is approximately 30.5% of its TTM revenue. The company achieved a high EBITDA margin of 44.77%, showing resilience despite regulatory headwinds in the derivatives segment. Diversification efforts are evident as the NBFC AUM reached ₹268.2 Cr and the Margin Trading Facility (MTF) AUM grew to ₹465.5 Cr. The institutional client base also saw significant growth, reaching 212 clients compared to 137 in previous periods.
Confidence: HIGH
What changedThe company has transitioned from a traditional brokerage to a fintech-focused entity with a significant increase in institutional clients (212) and a growing MTF book (₹465.5 Cr).
Why it mattersThe high EBITDA margin and diversification into NBFC and MTF lending reduce the company's historical reliance on volatile proprietary trading and derivative volumes, which are facing regulatory tightening.
Q1-FY27 Revenue: ₹448.1 CrQ1 Revenue vs TTM Revenue: 30.5%EBITDA Margin: 44.77%NBFC AUM: ₹268.2 CrMTF AUM: ₹465.5 CrGNPA (NBFC): 4.05%
📅 Short termThe stock may see positive momentum due to the strong margin performance and growth in the high-yield MTF and NBFC segments.
📈 Long termThe structural shift toward fee-based wealth management and technology-led retail broking could lead to a more stable and higher-quality earnings profile over the coming years.
⚠ Risk flags
- Regulatory changes to derivative contracts impacting trading volumes
- Relatively high GNPA of 4.05% in the NBFC segment
- Intense competition from low-cost fintech brokers
Key Highlights
Q1-FY27 Consolidated Revenue stood at ₹448.1 Cr with a PAT of ₹124.4 Cr.
EBITDA margin improved to 44.77% in Q1-FY27 from 38.79% in FY26.
NBFC segment reported an AUM of ₹268.2 Cr with a Net Interest Margin (NIM) of 4.44%.
Institutional client base expanded to 212, while the retail broking client base reached 48,061.
Utrade Algo platform subscriptions reached 72,507, with 6,543 paid plan subscribers.
👀 What to Watch
Investors should monitor the execution of the Wealth Management (AIF/PMS) rollout and the final NCLT approval for the Silverleaf acquisition. Additionally, track how the company manages its NBFC asset quality, as GNPA stands at 4.05%.
Thyrocare Q1 FY27: Pathology Revenue Grows 26% YoY; Franchisee Network Reaches 11,700+
Thyrocare reported a robust Q1 FY27 with consolidated revenue increasing 24% YoY, led by a 26% surge in its core pathology business. The company has successfully scaled its active franchisee network to over 11,700 centers, a fourfold increase since the 2021 management change. Management is now pivoting towards high-value 'Specialty Diagnostics' like genomics and allergy testing, targeting a 15-20% revenue share in the medium term. Despite adding 900 franchisees in Q1, the company maintains a conservative full-year net addition target of 1,700 to account for potential churn.
Confidence: HIGH
What changedThe company transitioned from a routine-testing focus to a high-growth, specialty-led diagnostic model with a significantly expanded physical lab and franchisee footprint.
Why it mattersThe 26% pathology growth confirms that Thyrocare is gaining market share under new management, while the shift to specialty tests aims to protect margins in a competitive diagnostic landscape.
Pathology Revenue Growth (YoY): 26%Consolidated Revenue Growth (YoY): 24%Active Franchisees: 11,700New Franchisees Added (Q1): 900Specialty Revenue Target: 15-20%
📅 Short termThe stock may see positive momentum as the 24-26% growth rates exceed the company's own long-term guidance of 18-22%.
📈 Long termThe expansion from 17 to 44 labs and a 4x increase in franchisees creates a structural competitive advantage in logistics and turnaround time for pan-India diagnostic services.
⚠ Risk flags
- Franchisee churn (management noted not all 900 Q1 additions may remain active)
- Intense pricing competition in the diagnostic industry
- Execution risk in the international foray into Africa
Key Highlights
Pathology business revenue grew 26% YoY in Q1 FY27, significantly outperforming the industry's mid-teen growth rates.
Active franchisee network reached 11,700+, adding 900 new partners in the first quarter alone.
Laboratory infrastructure expanded to 44 labs from 17 in FY21, with 100% of labs now NABL affiliated.
Aarogyam preventive health brand grew 21% YoY, while the Jaanch curative brand grew 36% YoY.
Test menu has expanded fivefold to more than 1,375 tests since the acquisition by API Holdings in 2021.
👀 What to Watch
Monitor the revenue contribution from the new 'Specialty Diagnostics' segment and the retention rate of the 900 franchisees added this quarter to gauge long-term scalability.
1,082 MWp Solar EPC Order Win from Leading Domestic Renewable Energy Company
Waaree Renewable Technologies Limited (WAAREERTL) has secured two Letters of Award (LOA) for the execution of ground-mounted Solar PV plants totaling 1,082 MWp (800 MWac). The projects, consisting of 530 MWp and 552 MWp units, are scheduled for completion during FY 2027-28. This win significantly bolsters the company's existing unexecuted order book of 3.48 GWp and provides clear revenue visibility for the next two fiscal years. While the specific contract value was not disclosed, the capacity is substantial compared to the 1,621 MWp executed in H1 FY26.
Confidence: HIGH
What changedThe company has added 1,082 MWp to its project pipeline, representing a significant expansion of its future workload beyond its current 3.48 GWp order book.
Why it mattersThis order confirms WAAREERTL's ability to win large-scale utility projects independently. The capacity is roughly 66% of the total volume executed in H1 FY26, ensuring the company stays on its high-growth trajectory (81% expected growth).
Total Capacity: 1,082 MWpProject 1 Capacity: 530 MWpProject 2 Capacity: 552 MWpExecution Deadline: FY 2027-28Existing Order Book: 3.48 GWp
📅 Short termThe announcement is likely to be viewed positively by the market as it validates the company's competitive positioning in the solar EPC segment and ensures future revenue.
📈 Long termThe company is successfully transitioning to GW-scale project execution. Sustained order wins of this magnitude support the high P/E valuation and the structural shift toward renewable energy in India.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Fixed-price contract risk (commodity price volatility)
- Execution delays could impact margins
- Dependency on parent company for module supply
Key Highlights
Total order capacity of 1,082 MWp (800 MWac) across two ground-mounted solar projects
Execution timeline set for completion within the financial year 2027-28
Adds to an existing unexecuted order book of 3.48 GWp as of the latest reporting
Projects involve full Engineering, Procurement, and Construction (EPC) works
Order awarded by a leading domestic renewable energy company, reducing reliance on parent-only contracts
👀 What to Watch
Monitor the company's quarterly execution pace to ensure it maintains the 1.6 GWp per half-year run rate required to clear the growing order book. Watch for margin trends in upcoming results, as these fixed-price EPC contracts are sensitive to solar module price volatility.
47.2% YoY PAT Growth: Share India Reports Record Q1 FY27 Net Profit of Rs 124.4 Cr
Share India Securities reported its highest-ever quarterly consolidated net profit of Rs 124.4 Cr for Q1 FY27, representing a 47.2% increase YoY. Revenue grew 31.3% YoY to Rs 448.1 Cr, while EBITDA margins expanded significantly to 44.8%. The growth was supported by a 47.8% YoY surge in Margin Trading Facility (MTF) AUM to Rs 465.5 Cr and an expansion of the institutional client base to 212. The board also declared an interim dividend of Rs 0.50 per share.
Confidence: HIGH
What changedShare India achieved record quarterly profitability and significant margin expansion, driven by its MTF and institutional broking segments.
Why it mattersThe results demonstrate a successful shift toward diversified, fee-based, and interest-based income streams, reducing the company's historical dependence on proprietary trading volatility.
Q1 FY27 Revenue: Rs 448.1 CrQ1 Revenue vs TTM Revenue: 30.5%Q1 Net Profit: Rs 124.4 CrMTF AUM: Rs 465.5 CrInterim Dividend: Rs 0.50 per shareNBFC Loan Book: Rs 268.2 Cr
📅 Short termThe stock is likely to react positively to the record profit and strong margin performance in the coming days.
📈 Long termThe company is structurally pivoting toward retail and institutional wealth management, which could lead to higher valuation multiples if growth in AUM and client base continues.
⚠ Risk flags
- NBFC GNPA remains relatively high at 4.05%
- Regulatory changes in derivative contracts could impact future trading volumes
Key Highlights
Consolidated Net Profit reached a record Rs 124.4 Cr, up 47.2% from the previous year's quarter.
EBITDA grew 45.2% YoY to Rs 200.6 Cr, with margins improving to 44.8%.
Margin Trading Facility (MTF) AUM increased 47.8% YoY to reach Rs 465.5 Cr.
NBFC asset quality improved with GNPA declining 25 bps QoQ to 4.05% and NNPA at 2.26%.
Institutional client base grew to 212, up from 137 reported in previous filings.
👀 What to Watch
Watch the earnings conference call on July 27, 2026, for updates on the Silverleaf acquisition and the impact of new SEBI derivative regulations on future volumes.
₹200 Cr Fundraise, ₹45 Cr Acquisition, and ₹0.50 Interim Dividend Announced
Share India Securities has approved a multi-pronged strategy including a ₹200 Cr debt fundraise and a ₹45 Cr acquisition. The company declared a 1st interim dividend of ₹0.50 per share (25% of face value) with a record date of July 30, 2026. The acquisition of Enshrine Leasing and Infotech (100% stake) is primarily to secure strategic control over an IT property in Mumbai. Additionally, the board approved Q1 FY27 results and authorized raising up to ₹200 Cr via NCDs and Commercial Papers to bolster its financial services operations.
Confidence: HIGH
What changedThe company has initiated a fresh debt fundraise and a strategic real estate-linked acquisition while maintaining its dividend payout schedule.
Why it mattersThe ₹200 Cr fundraise (approx. 4.7% of market cap) provides liquidity for business expansion, while the acquisition secures physical infrastructure in a key financial hub (Mumbai) to support long-term growth.
Debt Fundraise Limit: ₹200 CrAcquisition Cost: ₹45 CrInterim Dividend: ₹0.50 per shareFundraise vs Market Cap: ~4.76%Acquisition vs Net Worth: ~2.01%
📅 Short termThe stock may see interest leading up to the July 30 record date for the dividend; investors will also react to the Q1 FY27 earnings performance.
📈 Long termThe move to acquire infrastructure and raise debt suggests a focus on scaling the retail and institutional broking business, though regulatory changes in derivatives remain a structural headwind.
⚠ Risk flags
- Acquisition of a non-core IT/Real Estate entity
- Increased interest burden from the ₹200 Cr debt issuance
- Regulatory impact on derivative volumes affecting core revenue
Key Highlights
Declared 1st interim dividend of ₹0.50 per equity share for FY 2026-27
Approved debt fundraise of up to ₹200 Cr via NCDs and Commercial Papers on a private placement basis
Acquiring 100% of Enshrine Leasing and Infotech for up to ₹45 Cr, representing ~2% of company net worth
Target entity Enshrine Leasing had a turnover of ₹2.99 Cr in FY 2025-26
Record date for dividend eligibility set for July 30, 2026, with payment by August 22, 2026
👀 What to Watch
Monitor the deployment of the ₹200 Cr fundraise into high-yield segments like the Margin Trading Facility (MTF) and track the integration of the Mumbai IT property over the next 6 months.
Share India to Raise Rs 200 Cr Debt, Acquires Enshrine Leasing for Rs 45 Cr
Share India Securities has approved a debt fundraise of up to Rs 200 crore through NCDs and Commercial Papers to bolster its capital base. The company is also acquiring 100% of Enshrine Leasing and Infotech for up to Rs 45 crore, a move aimed at securing strategic control over an IT property in Mumbai. Additionally, the board declared a first interim dividend of Rs 0.50 per share for FY27. While the acquisition target has a small turnover of Rs 2.99 crore, the deal value reflects the underlying real estate assets.
Confidence: HIGH
What changedThe company is increasing its leverage by up to Rs 200 crore and expanding its asset base through the acquisition of a Mumbai-based IT property holding company.
Why it mattersThe fundraise provides liquidity for business expansion (likely Margin Trading Facility or proprietary trading), while the acquisition secures physical infrastructure in a key financial hub (Mumbai).
Debt Fundraise Limit: Rs 200 CrFundraise vs Net Worth: ~8.95%Acquisition Cost: Rs 45 CrTarget Turnover (FY26): Rs 2.99 CrInterim Dividend: Rs 0.50 per share
📅 Short termThe stock may see minor activity around the dividend record date (July 30); the fundraise and acquisition are unlikely to cause immediate price volatility.
📈 Long termThe acquisition of real estate infrastructure in Mumbai supports long-term operational scaling, though the immediate financial contribution from the acquired entity is negligible.
⚠ Risk flags
- High acquisition cost (Rs 45 Cr) relative to target turnover (Rs 2.99 Cr), though backed by property assets.
- Increased debt levels (up to Rs 200 Cr) in a high-interest-rate environment.
Key Highlights
Approved raising up to Rs 200 crore via debt securities including NCDs and Commercial Papers.
Acquisition of 100% equity in Enshrine Leasing and Infotech for a cost of up to Rs 45 crore.
Declared 1st interim dividend of Rs 0.50 per equity share (Face Value Rs 2) for FY 2026-27.
Enshrine Leasing reported a turnover of Rs 2.99 crore and net worth of Rs 3.17 crore as of March 2026.
Record date for the interim dividend is fixed for July 30, 2026, with payment by August 22, 2026.
👀 What to Watch
Investors should monitor the final terms of the Rs 200 crore debt issuance and the timeline for the Enshrine Leasing acquisition, expected to complete within six months.
Share India Declares ₹0.50 Dividend, ₹200 Cr Debt Fundraise, and ₹45 Cr Mumbai Acquisition
Share India Securities has announced a three-part corporate action: a ₹0.50 per share interim dividend, a ₹200 crore debt fundraise, and a ₹45 crore acquisition. The debt fundraise represents approximately 9% of the company's net worth and will likely support its Margin Trading Facility (MTF) expansion. The acquisition of Enshrine Leasing and Infotech for ₹45 crore is primarily a strategic real estate play to secure an IT Zone property in Mumbai. While the target's annual turnover is small at ₹2.99 crore, the acquisition aligns with the company's infrastructure growth objectives.
Confidence: HIGH
What changedThe company is increasing its leverage by up to ₹200 crore and expanding its physical infrastructure footprint in Mumbai through a 100% equity acquisition.
Why it mattersThe fundraise supports the strategic shift toward retail Margin Trading Facilities, while the acquisition provides permanent IT infrastructure in Mumbai, potentially reducing long-term leasing costs and supporting business expansion.
Interim Dividend: ₹0.50 per shareDebt Fundraise Amount: ₹200 CrAcquisition Cost: ₹45 CrFundraise vs Net Worth: ~8.95%Target Net Worth (Mar 2026): ₹317.47 LakhsDividend Record Date: July 30, 2026
📅 Short termThe dividend declaration and growth-oriented acquisition are likely to be viewed positively by the market in the coming weeks leading up to the record date.
📈 Long termThe acquisition of physical assets and the debt-funded expansion of the loan book (MTF) indicate a structural move to diversify revenue away from volatile proprietary trading.
⚠ Risk flags
- High acquisition premium (₹45 Cr for ₹3.17 Cr net worth)
- Increased debt levels
- Execution risk in scaling the MTF book
Key Highlights
Declared 1st Interim Dividend of ₹0.50 per equity share for FY 2026-27.
Approved raising up to ₹200 crore via debt securities (NCDs and Commercial Papers).
Acquiring 100% of Enshrine Leasing and Infotech Private Limited for a cost of up to ₹45 crore.
Record date for the interim dividend is fixed as July 30, 2026.
Target entity Enshrine Leasing reported a turnover of ₹299.34 lakhs (₹2.99 cr) for FY 2025-26.
👀 What to Watch
Investors should monitor the specific terms of the ₹200 crore debt issuance and the subsequent impact on interest coverage ratios, as well as the execution of the MTF expansion strategy.
47.4% YoY Profit Growth: Share India Reports Rs 124.41 Cr Consolidated PAT in Q1 FY27
Share India Securities delivered a strong performance for Q1 FY27, with consolidated net profit rising 47.4% YoY to Rs 124.41 Cr. Operating margins expanded significantly to 45.45% from 42.01% in the same quarter last year, reflecting improved efficiency. The company also announced the early redemption of Rs 99.90 Cr worth of NCDs due to administrative difficulties in revising the end-use of proceeds. Despite previous concerns regarding regulatory changes in derivatives, the quarterly EPS improved to Rs 5.67 from Rs 3.86 YoY.
Confidence: HIGH
What changedThe company reported a sharp recovery in profitability and margins compared to the preceding quarter (Q4 FY26), while also deciding to retire Rs 99.90 Cr of debt early.
Why it mattersThe strong margin expansion and profit growth suggest the company is successfully navigating regulatory headwinds in the derivatives segment, which had previously impacted revenue.
Consolidated PAT (Q1 FY27): Rs 124.41 CrYoY PAT Growth: 47.4%Operating Margin: 45.45%NCD Redemption Value: Rs 99.90 CrDebt/Equity Ratio: 0.21
📅 Short termThe stock is likely to react positively to the strong earnings beat and margin improvement over the next few weeks.
📈 Long termThe structural shift toward retail and fee-based income (Wealth Management) is critical for long-term valuation re-rating as it reduces proprietary trading risks.
⚠ Risk flags
- Regulatory changes in derivative contracts impacting trading volumes
- Dependency on stock exchange infrastructure
- Pending NCLT approval for Silverleaf acquisition
Key Highlights
Consolidated Net Profit grew 47.4% YoY to Rs 124.41 Cr for the quarter ended June 30, 2026
Operating margins improved to 45.45% compared to 42.01% in the year-ago period
Basic EPS increased to Rs 5.67 from Rs 3.86 in Q1 FY26
Board approved early redemption of 9,990 NCDs aggregating to Rs 99.90 Cr
Consolidated Debt-to-Equity ratio remains healthy at 0.21 times
👀 What to Watch
Investors should monitor the final NCLT approval for the Silverleaf acquisition and the execution of the diversification strategy into Wealth Management (AIF/PMS) to reduce reliance on proprietary trading.
Thyrocare Q1 FY27 Revenue Grows 24% YoY to ₹240 Cr; Resubmits Results in Machine-Readable Format
Thyrocare Technologies reported a strong start to FY27 with consolidated revenue reaching ₹240.02 Cr, a 24.3% increase from ₹193.03 Cr in Q1 FY26. Profit before tax (PBT) saw a significant jump of 35.3% YoY to ₹68.29 Cr, driven by the core Diagnostic Testing segment which contributed 94% of total revenue. The company maintained healthy margins with standalone EPS rising to ₹3.15 from ₹2.27 YoY. This specific filing is a procedural resubmission in a machine-readable format as requested by the NSE.
Confidence: HIGH
What changedThe company resubmitted its previously announced Q1 FY27 financial results in a machine-readable format following a compliance request from the National Stock Exchange.
Why it mattersThe results confirm that Thyrocare is outperforming the broader diagnostic industry's mid-teen growth rates, demonstrating strong execution in its core pathology business and effective cost management.
Consolidated Revenue (Q1 FY27): ₹240.02 CrRevenue vs TTM Revenue: 29.4%Consolidated PBT: ₹68.29 CrStandalone EPS: ₹3.15Diagnostic Segment Revenue: ₹226.21 Cr
📅 Short termThe stock may react positively to the strong double-digit growth in both revenue and profitability reported for the first quarter.
📈 Long termThe company's focus on high-volume, affordable diagnostics and its expansion into international markets like Tanzania provide a structural growth runway.
⚠ Risk flags
- Competitive pricing pressure in the diagnostic market
- Seasonality (Q3 is typically a soft quarter)
- High dependence on the franchise/B2B network
Key Highlights
Consolidated revenue for Q1 FY27 grew 24.3% YoY to ₹240.02 Cr
Profit before tax (PBT) increased by 35.3% YoY to ₹68.29 Cr from ₹50.48 Cr
Diagnostic Testing Services revenue reached ₹226.21 Cr, up from ₹178.33 Cr in the previous year's quarter
Standalone net profit for the quarter stood at ₹50.17 Cr compared to ₹36.05 Cr YoY
Imaging Services segment contributed ₹13.48 Cr to the total revenue
👀 What to Watch
Investors should monitor the sustainability of the 24% revenue growth rate against the company's long-term target of 18-22% and track the expansion of the franchise network which currently adds 100-150 centers monthly.
41% Adjusted EBITDA Margin in FY26; Saregama Reports ₹404.7 Cr Adjusted EBITDA
Saregama's FY26 corporate presentation highlights a high-margin IP monetization strategy, with Adjusted EBITDA reaching ₹404.7 Cr at a 41% margin. While headline revenue dipped to ₹984.6 Cr from ₹1,171.3 Cr in FY25 due to the absence of one-off large-scale live events (Diljit Dosanjh tour), the core music licensing business remains robust. The company maintains a disciplined 5-year payback rule for its 1,80,000+ song library, which now generates 60% of licensing revenue from content released after 2000. Strategic focus remains on capturing 25-30% of all new Indian music through partnerships like Bhansali Productions.
Confidence: HIGH
What changedThe company released its updated corporate presentation detailing FY26 financial performance and its strategic roadmap as a 'Digital IP Powerhouse'.
Why it mattersIt confirms the high-margin, annuity-like nature of Saregama's music IP, where content earns for 60-80 years after an initial 5-year investment recovery period.
FY26 Adjusted EBITDA: ₹404.7 CrFY26 Revenue: ₹984.6 CrEBITDA Margin: 41%Music Library Size: 1,80,000+ songsFY26 Revenue vs TTM Revenue: 130.4%
📅 Short termThe market is likely to view the 41% EBITDA margin and the explanation for the revenue dip (one-off events in the base year) as a sign of underlying business strength.
📈 Long termThe structural shift toward paid music streaming in India (currently only 3% penetration) provides a multi-year growth runway for Saregama's IP library.
⚠ Risk flags
- High acquisition costs for new music rights
- Dependency on third-party platforms like YouTube and Spotify
- Lumpy nature of the Live Events business
Key Highlights
Adjusted EBITDA reached an all-time high of ₹404.7 Cr in FY26, representing a 41% margin.
Owned music library exceeds 1,80,000 songs, with 60% of licensing revenue coming from songs released post-2000.
Digital audience reach expanded to 650 million+ subscribers and followers across the portfolio.
New music investments show a 26% IRR, with steady-state margins rising to ~90% after the initial 5-year payback period.
Revenue mix is dominated by Music (83%), followed by Video (11%) and Live Events (6%).
👀 What to Watch
Monitor the execution of the Bhansali Productions partnership and the growth of the 'Artiste Management' vertical, which is expected to be a high-growth driver alongside digital music streaming.
₹256 Cr Brand Divestment and ₹900 Cr Cash Surplus Highlighted at 68th AGM
TTK Healthcare reported FY26 revenue of ₹857.28 cr, a 7% growth, though pre-tax profit fell to ₹82.56 cr due to the loss of USAID tender business in the Protective Devices segment. The company announced the divestment of its 'EVA' and 'Good Home' brands to Wipro Enterprises for ₹256 cr, which contributed ₹148 cr to FY26 revenue. Most notably, the company now holds a massive cash balance of ~₹900 cr, representing approximately 61% of its current market capitalization. A dividend of ₹10 per share (100%) was recommended.
Confidence: HIGH
What changedThe company is divesting two major consumer brands (EVA and Good Home) and has significantly increased its cash reserves to ₹900 cr.
Why it mattersThe brand sale represents ~30% of TTM revenue and provides a massive liquidity cushion, though it creates a temporary revenue gap that needs to be filled by other segments like Ortho or new acquisitions.
Brand Divestment Value: ₹256 crDivestment vs TTM Revenue: ~30%Cash Balance: ₹900 crCash vs Market Cap: ~61%FY26 Revenue Growth: 7%Dividend per Share: ₹10.00
📅 Short termThe stock may see positive sentiment due to the high valuation achieved for the brand divestment and the substantial cash-per-share floor.
📈 Long termThe company is undergoing a structural shift, moving away from certain consumer segments toward medical devices and animal welfare; long-term value depends on the efficient allocation of the ₹900 cr cash pile.
⚠ Risk flags
- Loss of high-margin institutional/tender business (USAID)
- Revenue concentration risk following brand divestments
- Execution risk in clinical trials for new medical devices
Key Highlights
Divestment of EVA and Good Home brands to Wipro for ₹256 cr plus GST
Cash and bank balances reached ~₹900 cr as of March 31, 2026
Ortho Division reported strong revenue growth of 27% in FY26
Divested brands (EVA and Good Home) had a combined turnover of ₹148 cr in FY26
Proposed pivotal clinical study for TC2 Titanium Heart Valve involving 400 patients
👀 What to Watch
Monitor the deployment strategy for the ₹900 cr cash surplus, as the company continues to divest non-core brands. Investors should track the margin impact of losing the ₹148 cr consumer brand revenue versus the interest income or acquisition potential from the new cash inflow.
